What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
David Perlmutters research on alterations in glutathione levels, there seems to be both a clinical and neuropathological difference in PD patients treated with IV glutathione versus control groups
Oxcarbazine (252 g/mol) LogP: Carbamazepine 2.45
Appl Biochem Biotechnol 168:198205
Tirzepatide does not directly burn fat like a stimulant
Taken together, these studies highlight GLP1-Ss potential as a valuable research tool for exploring the neuroendocrine regulation of appetite and long-term body weight control
